Medullary Thyroid Carcinoma
📧 Sign up to get email alerts when something new happens for Medullary Thyroid Carcinoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-06-15FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
The FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation.
-
FDA label_change · 2020-06-05FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
FDA reviewed and approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation to update labeling.
-
CLINICAL_TRIALS trial_result · 2020-02-13Clinical Trial Update: Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma [Phase 2]
Phase 2 study of sulfatinib for advanced medullary thyroid carcinoma and iodine-refractory differentiated thyroid carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2019-05-21Clinical Trial Update: Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) [Phase 2, Phase 3]
A study evaluating anlotinib in medullary thyroid carcinoma has completed Phase 2 and Phase 3 trials.
-
CLINICAL_TRIALS trial_result · 2018-12-21Clinical Trial Update: Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer [Phase 2]
Phase 2 trial evaluating sorafenib tosylate for metastatic, locally advanced, or recurrent medullary thyroid cancer; study completed with re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-10-12FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
The FDA approved a supplemental application for Caprelsa (vandetanib) submitted by Genzyme Corporation.
-
CLINICAL_TRIALS trial_result · 2018-05-22Clinical Trial Update: Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients
A clinical trial assessing quality-of-life measurement tools in patients with medullary thyroid carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2018-04-05Clinical Trial Update: Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
This completed clinical trial update from the National Cancer Institute investigates molecular pathways in medullary thyroid carcinoma and c…
-
CLINICAL_TRIALS trial_result · 2017-09-15Clinical Trial Update: Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery [Phase 2]
This Phase 2 trial evaluated Sunitinib malate in iodine-refractory thyroid cancers, including differentiated and medullary subtypes. Results…
-
CLINICAL_TRIALS trial_result · 2017-08-03Clinical Trial Update: Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients [Phase 2]
This update reports the completion of Bayer-sponsored Phase II trial evaluating sorafenib in Japanese patients with anaplastic or medullary …
-
CLINICAL_TRIALS trial_result · 2017-06-06Clinical Trial Update: Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study [NA]
Pre-operative nodal staging of thyroid cancer evaluated with USPIO MRI in a preliminary study; results have been posted.
-
CLINICAL_TRIALS trial_result · 2017-05-17Clinical Trial Update: A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) [Phase 1, Phase 2]
Phase I/II trial evaluating vandetanib (ZD6474) plus bortezomib in adults with medullary thyroid carcinoma; study status TERMINATED with res…
-
FDA approval · 2017-05-16FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
The FDA approved a supplemental application for Caprelsa (vandetanib) submitted by Genzyme Corporation.
-
CLINICAL_TRIALS trial_result · 2017-05-02Clinical Trial Update: Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib [Phase 1]
A Phase 1 study in healthy volunteers to assess whether omeprazole and ranitidine alter the pharmacokinetics of vandetanib, a therapy used f…
-
CLINICAL_TRIALS trial_result · 2017-05-02Clinical Trial Update: CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice
A Belgian registry study evaluating the use of vandetanib (Caprelsa) in current clinical practice for metastatic medullary thyroid carcinoma…
-
CLINICAL_TRIALS trial_result · 2017-04-25Clinical Trial Update: Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer [Phase 2]
A Phase 2 trial evaluating sunitinib malate for iodine-refractory recurrent or metastatic thyroid cancer has completed enrollment and posted…
-
CLINICAL_TRIALS safety_alert · 2016-08-31Clinical Trial Update: Vandetanib Risk Minimisation Effectiveness
This update reports on the effectiveness of risk minimisation measures for vandetanib in medullary thyroid carcinoma, based on the completed…
-
FDA approval · 2016-07-28FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
The FDA approved a supplemental application for Caprelsa (vandetanib) from Genzyme Corporation.
-
CLINICAL_TRIALS trial_result · 2016-07-15Clinical Trial Update: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma [Phase 1]
Phase 1 clinical trial evaluating the combination of Cixutumumab, Everolimus, and Octreotide acetate in patients with advanced low- to inter…
-
FDA label_change · 2016-05-20FDA Approved: COMETRIQ — Supplemental Application (Exelixis, Inc.)
FDA approved a supplemental application for COMETRIQ (cabozantinib) submitted by Exelixis, Inc.
-
CLINICAL_TRIALS trial_result · 2016-04-25Clinical Trial Update: SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer [Phase 2]
Phase 2 clinical trial evaluating SOM230 alone or in combination with RAD001 for medullary thyroid carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2016-03-17Clinical Trial Update: Ponatinib for Advanced Medullary Thyroid Cancer [Phase 2]
A Phase 2 trial of ponatinib for advanced medullary thyroid carcinoma was terminated, with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2015-11-27Clinical Trial Update: To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer [Phase 4]
A Phase 4 trial comparing two doses of vandetanib in patients with advanced medullary thyroid carcinoma has completed. Results were posted o…
-
CLINICAL_TRIALS trial_result · 2015-05-19Clinical Trial Update: Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma [Phase 1, Phase 2]
Phase 1/2 clinical trial results show vandetanib was evaluated for safety and tolerability in Japanese patients with unresectable locally ad…
-
CLINICAL_TRIALS trial_result · 2014-12-17Clinical Trial Update: Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma [Phase 1, Phase 2]
A terminated Phase 1/2 clinical trial evaluated Imatinib in combination with Dacarbazine and Capecitabine for medullary thyroid carcinoma.